Detalhe da pesquisa
1.
A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
BMC Cancer
; 21(1): 749, 2021 Jun 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34187401
2.
Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma.
Future Oncol
; 16(13): 817-825, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32223334
3.
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
J Clin Oncol
; 41(14): 2607-2616, 2023 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36763945
4.
A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3.
Neurooncol Adv
; 3(1): vdab075, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34377985